Cargando…

Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring

BACKGROUND: Different studies, mostly with limited cohorts, have suggested the effects of patients’ characteristics on levodopa (LD) pharmacokinetics. OBJECTIVE: We primarily aimed at investigating in a large population the relationship between patients’ features and LD kinetic variables, to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contin, Manuela, Lopane, Giovanna, Belotti, Laura M.B., Galletti, Margherita, Cortelli, Pietro, Calandra-Buonaura, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837688/ https://www.ncbi.nlm.nih.gov/pubmed/36373294 http://dx.doi.org/10.3233/JPD-223374

Ejemplares similares

Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease
por: Ursino, Mauro, et al.
Publicado: (2020)

Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort
por: Contin, Manuela, et al.
Publicado: (2021)

A Mathematical Model of Levodopa Medication Effect on Basal Ganglia in Parkinson's Disease: An Application to the Alternate Finger Tapping Task
por: Baston, Chiara, et al.
Publicado: (2016)

Case report: Bilateral double beta peak activity is influenced by stimulation, levodopa concentrations, and motor tasks, in a Parkinson’s disease patient on chronic deep brain stimulation
por: Giannini, Giulia, et al.
Publicado: (2023)

How resistant are levodopa‐resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Effects of Helicobacter pylori on Levodopa Pharmacokinetics
por: Nyholm, Dag, et al.
Publicado: (2021)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
por: Adamiak-Giera, Urszula, et al.
Publicado: (2021)

Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration
por: Nedorubov, Andrey Anatolievich, et al.
Publicado: (2019)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure: Potential Red Flag for Future Multiple System Atrophy
por: Baschieri, Francesca, et al.
Publicado: (2017)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Levodopa-Induced Pseudopheochromocytoma
por: Cardoso, Joana, et al.
Publicado: (2023)

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease
por: Nagayama, Hiroshi, et al.
Publicado: (2015)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: A case report
por: Ko, Pan-Woo, et al.
Publicado: (2018)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Mathematical Insights into the Effects of Levodopa
por: Reed, Michael C., et al.
Publicado: (2012)

Thrombocytopenia Associated with Levodopa Treatment
por: Lee, Ku-Eun, et al.
Publicado: (2013)

Orthostatic stability with intravenous levodopa
por: Siddiqi, Shan H., et al.
Publicado: (2015)

The Human Experience with Intravenous Levodopa
por: Siddiqi, Shan H., et al.
Publicado: (2016)

Levodopa: History and Therapeutic Applications
por: Ovallath, Sujith, et al.
Publicado: (2017)

Levodopa-Associated Barking Vocalizations
por: Prasad, Shweta, et al.
Publicado: (2021)

Freezing of Gait Before Levodopa
por: Nonnekes, Jorik, et al.
Publicado: (2021)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

REM Sleep Behaviour Disorder in Multiple System Atrophy: From Prodromal to Progression of Disease
por: Giannini, Giulia, et al.
Publicado: (2021)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2020)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
por: Imbeah, Emelia Priscilla, et al.
Publicado: (2022)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ulaei5sc68hnfpp975q4kdlvuq